Open-Label Access to ATH434 for Patients Who Completed Study ATH434-201 in France
← catalyst calendarNCT07729852 · readout ≤ 1,076 d
Sponsored by Alterity Therapeutics (industry) · ATHE — their whole pipeline →.
Phase
Phase 2
Status
Not yet recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
5estimated
Sites
4
Country
France
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Jul 2026 | estimated | When the study began enrolling |
| Primary completion | Jul 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jul 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Multiple System Atrophy
Intervention
- Drug: ATH434 — also filed as PBT434
Primary outcomes
what the primary-completion date above is the date OFIncidence, Severity, and Relationship of Adverse Events (AEs) and Serious Adverse Events (SAEs)
measured Baseline to completion of study treatment, an average of 1 year.
Change From Baseline in Clinical Laboratory Parameters
measured Baseline to completion of study treatment, an average of 1 year.
Change From Baseline in Vital Signs
measured Baseline to completion of study treatment, an average of 1 year.
Duration of Exposure to ATH434
measured Baseline to completion of study treatment, an average of 1 year.
Cumulative Dose of ATH434
measured Baseline to completion of study treatment, an average of 1 year.
Permalink · ATHE's whole pipeline · Catalyst calendar · Every registered study · What changed